[{"orgOrder":0,"company":"Remedium","sponsor":"Tufts University","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"RMD 1101","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Remedium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedium \/ Tufts University","highestDevelopmentStatusID":"4","companyTruncated":"Remedium \/ Tufts University"},{"orgOrder":0,"company":"Remedium","sponsor":"Exothera","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"RMD 1101","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Remedium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Remedium \/ Remedium","highestDevelopmentStatusID":"4","companyTruncated":"Remedium \/ Remedium"}]

Find Clinical Drug Pipeline Developments & Deals by Remedium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Remedium and Exothera will demonstrate the industrialization potential of Remedium’s RMD 1101 (AAV2-FGF18). Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18 for the tr...

                          Brand Name : RMD 1101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 22, 2023

                          Lead Product(s) : RMD 1101

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Preclinical

                          Recipient : Exothera

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Through this partnership, Remedium aims to characterize the functionality of its lead candidate RMD 1101, in a range of in vitro, ex vivo, and in vivo efficacy models that will help to advance it toward IND.

                          Brand Name : RMD 1101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 15, 2021

                          Lead Product(s) : RMD 1101

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Preclinical

                          Sponsor : Tufts University

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank